Adjuvant combination reduces recurrence risk in early liver cancer

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.An estimated 70% to 80% of people with early-stage hepatocellular carcinoma experience disease recurrence after surgery.The randomized phase 3 IMbrave050 study included 662 people with early-stage HCC at high risk for recurrence after resection or ablation with curative intent.Researchers randomly assigned half of study participants to atezolizumabRead More

Generated by Feedzy